Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1988 2
1989 2
1990 1
2010 1
2011 2
2012 7
2013 7
2014 3
2015 4
2016 2
2018 1
2019 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.
Drozd C, Curtit E, Jacquinot Q, Marquine C, Mansi L, Chaigneau L, Dobi E, Viot J, Meynard G, Paillard MJ, Goujon M, Roux P, Vernerey D, Gillet V, Bourdin H, Galli S, Meneveau N, Mougin F. Drozd C, et al. Among authors: dobi e. BMC Cancer. 2023 May 17;23(1):449. doi: 10.1186/s12885-023-10902-6. BMC Cancer. 2023. PMID: 37198562 Free PMC article. Clinical Trial.
Cabazitaxel: a novel microtubule inhibitor.
Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X. Villanueva C, et al. Among authors: dobi e. Drugs. 2011 Jul 9;71(10):1251-8. doi: 10.2165/11591390-000000000-00000. Drugs. 2011. PMID: 21770474 Review.
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.
Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F. Jacquinot Q, et al. Among authors: dobi e. Front Cardiovasc Med. 2022 Sep 23;9:1000846. doi: 10.3389/fcvm.2022.1000846. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36211552 Free PMC article.
[KIT and KIT: from biology to clinical use].
Curtit E, Mansi L, Viel E, Dobi E, Chaigneau L, Nguyen T, Pivot X, Blay JY, Kalbacher E. Curtit E, et al. Among authors: dobi e. Bull Cancer. 2012 Feb 1;99(2):191-7. doi: 10.1684/bdc.2011.1386. Bull Cancer. 2012. PMID: 21669561 Free article. French.
[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté].
Dénommé F, Kroemer M, Montcuquet P, Nallet G, Thiery-Vuillemin A, Bazan F, Mouillet G, Villanueva C, Demarchi M, Stein U, Almotlak H, Chaigneau L, Curtit E, Meneveau N, Maurina T, Dobi E, Hon TN, Cals L, Mansi L, Verlut C, Pana-Katatali H, Caubet M, Paillard MJ, Limat S, Pivot X, Nerich V. Dénommé F, et al. Among authors: dobi e. Bull Cancer. 2016 Oct;103(10):849-860. doi: 10.1016/j.bulcan.2016.08.007. Epub 2016 Sep 29. Bull Cancer. 2016. PMID: 27692731 French.
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, Bonnetain F, Villanueva C. Pivot X, et al. Among authors: dobi e. Oncologist. 2015 Apr;20(4):344-50. doi: 10.1634/theoncologist.2014-0198. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795632 Free PMC article. Clinical Trial.
33 results